Title: Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?
Authors: Steiner, Johann
Walter, Martin
Gos, Tomasz
Guillemin, Gilles J
Bernstein, Hans-Gert
Sarnyai, Zoltan
Mawrin, Christian
Brisch, Ralf
Bielau, Hendrik
Meyer zu Schwabedissen, Louise
Bogerts, Bernhard
Myint, Aye-Mu
Issue Date: 10-Aug-2011
Abstract: Abstract Background Immune dysfunction, including monocytosis and increased blood levels of interleukin-1, interleukin-6 and tumour necrosis factor α has been observed during acute episodes of major depression. These peripheral immune processes may be accompanied by microglial activation in subregions of the anterior cingulate cortex where depression-associated alterations of glutamatergic neurotransmission have been described. Methods Microglial immunoreactivity of the N-methyl-D-aspartate (NMDA) glutamate receptor agonist quinolinic acid (QUIN) in the subgenual anterior cingulate cortex (sACC), anterior midcingulate cortex (aMCC) and pregenual anterior cingulate cortex (pACC) of 12 acutely depressed suicidal patients (major depressive disorder/MDD, n = 7; bipolar disorder/BD, n = 5) was analyzed using immunohistochemistry and compared with its expression in 10 healthy control subjects. Results Depressed patients had a significantly increased density of QUIN-positive cells in the sACC (P = 0.003) and the aMCC (P = 0.015) compared to controls. In contrast, counts of QUIN-positive cells in the pACC did not differ between the groups (P = 0.558). Post-hoc tests showed that significant findings were attributed to MDD and were absent in BD. Conclusions These results add a novel link to the immune hypothesis of depression by providing evidence for an upregulation of microglial QUIN in brain regions known to be responsive to infusion of NMDA antagonists such as ketamine. Further work in this area could lead to a greater understanding of the pathophysiology of depressive disorders and pave the way for novel NMDA receptor therapies or immune-modulating strategies.
Description: RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.
URI: http://www.dspace.cam.ac.uk/handle/1810/239025
Other Identifiers: http://dx.doi.org/10.1186/1742-2094-8-94
Appears in Collections:Scholarly works - Chemical Engineering and Biotechnology

Files in This Item:

File Description SizeFormat
1742-2094-8-94.xml85.97 kBXMLView/Open
1742-2094-8-94.pdf1.2 MBAdobe PDFThumbnail
View/Open
Additional resources for this item
search for alternative versions in eresources@cambridge
retrieve citation metadata in EndNote format

This item has been accessed 452 times.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.